Elenagen DNA Plasmid Therapy Shows Significant Promise in Alleviating Chronic Pain in Dogs with Osteoarthritis

Researchers at CureLab Oncology have announced that their DNA plasmid therapy, Elenagen, has shown a 90% success rate in alleviating chronic pain in dogs with osteoarthritis. This breakthrough therapy, which was previously shown to be safe and effective against lethal ovarian cancer, reprograms aged or dysfunctional mesenchymal stem cells to regain a youthful phenotype and resume secreting anti-inflammatory factors. In a peer-reviewed study published in Frontiers in Veterinary Science, Elenagen reduced osteoarthritis pain scores in companion dogs, offering a promising translational signal for non-opioid pain medicine.

Key Takeaways:

• Elenagen, a DNA plasmid therapy, has shown a 90% success rate in alleviating chronic pain in dogs with osteoarthritis, with no treatment-related adverse events observed.
• The therapy reprograms aged or dysfunctional mesenchymal stem cells to regain a youthful phenotype and resume secreting anti-inflammatory factors, which travel over long distances to induce beneficial changes in remote MSCs.
• Weekly p62 plasmid injections reduced limping and restored playful activity in dogs with severe osteoarthritis pain, with most dogs exhibiting near-complete improvement by six doses.
• The successful validation of Elenagen's hypothesis may signal a potential, disease-modifying approach to treating chronic pain in both veterinary and human medicine.
• CureLab Oncology has plans to conduct larger, placebo-controlled trials in both dogs and humans in 2026 to further validate Elenagen's efficacy and safety.
• Elenagen's well-established safety profile from prior human cancer trials significantly de-risks and accelerates its potential development pathway for pain management in both veterinary and human medicine.
• The company plans to incorporate chronic pain monitoring into its FDA and EMA cancer clinical trials starting in 2026, suggesting a highly synergistic therapeutic profile.

Statistics:

• 90% success rate in alleviating chronic pain in dogs with osteoarthritis
• 90% of dogs achieved at least a one-point drop in Pain Severity Score and a two-point drop in Pain Interference Score after ten weekly intramuscular injections
• Median Pain Severity fell from 5.25 to 3.25, and median Pain Interference from 7.00 to 3.27, by day 70
• 17 dogs aged 4-13 years were included in the study
• Weekly p62 plasmid injections reduced limping and restored playful activity in dogs with severe osteoarthritis pain

Sources:

• CureLab Oncology (www.curelab.com)
• Frontiers in Veterinary Science (DOI: 10.3389/fvets.2025.1519881)
• Contify.com (2017)